Breaking News, Collaborations & Alliances

Amunix, Biogen In Blood Factor Research Pact

Amunix, Inc. has entered into an exclusive worldwide research collaboration with Biogen Idec to research and develop novel, fully-recombinant blood factors (Factors IX, VIII and VIIa) with improved therapeutic properties.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amunix, Inc. has entered into an exclusive worldwide research collaboration with Biogen Idec to research and develop novel, fully-recombinant blood factors (Factors IX, VIII and VIIa) with improved therapeutic properties. The partnership leverages Amunix’s protein half-life engineering expertise using its XTEN technology, with Biogen’s capabilities in research, manufacturing and clinical development of recombinant blood factors for hemophilia. The companies will jointly conduct pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters